Publications by authors named "Venugopal B"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

36

Total Likes

350

Extended Reach

2,768,266

Social Features

167
I
Image reconstruction and analysis of atherosclerosis imaging by [F]FDG PETCT using digital PET technology.
Stephen Rankin, A J Gemmell, J McClure, B Venugopal, P J Slomka

Eur J Nucl Med Mol Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review.
Natalie Charnley, Kate Fife, Daniel Y C Heng, James Larkin, John McGrane

Cancer Treat Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Health Associations of Apical Periodontitis: A Systematic Review of Observational Studies.
Balaji Venugopal, Hemamalini Narasimman, Ananthi Mahalingam, R Naren Kishore, Kavitha Jayavel

Cureus· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.
Stephen J H Dobbin, Kenneth Mangion, Colin Berry, Giles Roditi, Susmita Basak

Heart· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
Laurence Albiges, Thomas Powles, Anand Sharma, Balaji Venugopal, Jens Bedke

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
T K Choueiri, K Penkov, H Uemura, M T Campbell, S Pal

Ann Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
Thomas Powles, Toni K Choueiri, Laurence Albiges, Katriina Peltola, Guillermo de Velasco

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients.
Stephen Rankin, Caitlin Fountain, Alastair J Gemmell, Daire Quinn, Alasdair Henderson

Clin Sci (Lond)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.
Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba

Eur Urol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, James Larkin, Tom Powles

Contemp Clin Trials Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
Paul Nathan, Balaji Venugopal, Jamshed Ali, Jennifer Allison, Mariangela Ceruso

Clin Genitourin Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis.
Benjamin M P Elyan, Michael K Sullivan, James Hedley, Nicole De La Mata, Angela C Webster

BJC Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma-Systematic Literature Review of Clinical and Real-World Evidence.
Anand Sharma, Amit Bahl, Ricky Frazer, Esha Godhania, Nicholas Halfpenny

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report.
Pramod Kumar, Pradeep Krishna, Ravindra Nidoni, C K Adarsh, M G Arun

Am J Transplant· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using F-FDG positron emission tomography.
Stephen Rankin, Caitlin Fountain, Alastair J Gemmell, Daire Quinn, Alasdair Henderson

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials.
Stephen Rankin, Benjamin Elyan, Robert Jones, Balaji Venugopal, Patrick B Mark

JACC CardioOncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote vision-based digital patient monitoring of pulse and respiratory rates in acute medical wards.
Adam Lewis, Bindia Venugopal, Varsha Gandhi, Oliver Gibson, Laura Swanton

Thorax· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Marine Gross-Goupil, Lubomir Bodnar, Matthew T Campbell, Agnieszka Michael, Balaji Venugopal

Clin Genitourin Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, Lisa Pickering, Tom Waddell

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka

NEJM Evid· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto

N Engl J Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis